HIMS (Hims & Hers Health) Growth Rank: 10 (As of Aug. 12, 2026) — 11% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HIMS Hims & Hers Health Inc HIMS
81 GF Score
Price $29.50
GF Value $41.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Hims & Hers Health Growth Rank?

Hims & Hers Health HIMS -3.32% 81 Growth Rank is 10 as of Aug. 12, 2026, which is 11% above its 10-year median of 9.00. GuruFocus rates HIMS with a GF Score™ of 81/100 and a GF Value™ of $41.18 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Hims & Hers Health has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Hims & Hers Health Growth Rank Related Terms

HIMS vs LNTH, AMRX, LQDA: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hims & Hers Health's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hims & Hers Health Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hims & Hers Health's Growth Rank distribution charts can be found below:

* The bar in red indicates where Hims & Hers Health's Growth Rank falls into.


HIMS
81GF Score
Hims & Hers Health Inc HIMS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Hims & Hers Health (HIMS) has a Growth Rank of 10 as of Aug. 12, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Hims & Hers Health and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Hims & Hers Health's Growth Rank has ranged from 9.00 to 10.00.
Is Hims & Hers Health's Growth Rank too high?
Hims & Hers Health's current Growth Rank of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 9.00 to a high of 10.00. Overall, Hims & Hers Health has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Growth Rank compare to LNTH and AMRX?
Hims & Hers Health's Growth Rank of 10 can be compared against companies in the Drug Manufacturers industry. Historically, Hims & Hers Health's own Growth Rank has ranged from 9.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Hims & Hers Health and its competitors. Hims & Hers Health's current Growth Rank is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (HIMS) is currently considered Modestly Undervalued. The stock's GF Value™ is $41.18, compared to a current price of $29.50 — trading 28.4% below its estimated fair value. The current Growth Rank is 10, which is 11% above median its 10-year median of 9.00. Hims & Hers Health's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Hims & Hers Health (HIMS), the current Growth Rank is 10 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hims & Hers Health (HIMS) Overvalued in 2026?

Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued. The current stock price of $29.50 is trading 28.4% below its estimated GF Value™ of $41.18. GuruFocus considers Hims & Hers Health to be Modestly Undervalued.

Key valuation signals for HIMS:

  • Growth Rank: 10 (11% above median its 10-year median of 9.00)
  • GF Value™: $41.18 vs. price of $29.50 (28.4% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the HIMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hims & Hers Health Business Description

Other Exchanges HIMS:Mexico82W:Germany
Address 2269 Chestnut Street, No. 523, San Francisco, CA, USA, 94123
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
81GF Score

Get the complete analysis for HIMS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.50
Price
$41.18
GF Value